HeartSciences Inc. (NASDAQ:HSCS – Get Free Report) saw a large decrease in short interest in July. As of July 15th, there was short interest totaling 77,601 shares, a decrease of 37.2% from the June 30th total of 123,640 shares. Based on an average daily volume of 58,703 shares, the short-interest ratio is currently 1.3 days. Approximately 2.6% of the company’s stock are short sold.
Hedge Funds Weigh In On HeartSciences
An institutional investor recently raised its position in HeartSciences stock. Geode Capital Management LLC boosted its holdings in HeartSciences Inc. (NASDAQ:HSCS – Free Report) by 110.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,928 shares of the company’s stock after purchasing an additional 14,150 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of HeartSciences worth $83,000 at the end of the most recent quarter. Institutional investors own 17.24% of the company’s stock.
HeartSciences Stock Performance
Shares of HSCS stock traded down $0.08 during trading hours on Thursday, hitting $2.08. 69,158 shares of the company were exchanged, compared to its average volume of 1,003,643. The stock has a market capitalization of $8.11 million, a price-to-earnings ratio of -0.53 and a beta of 1.78. HeartSciences has a one year low of $1.63 and a one year high of $3.93. The business’s 50-day simple moving average is $2.30 and its two-hundred day simple moving average is $2.48.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, HeartSciences has an average rating of “Hold” and an average target price of $8.00.
Check Out Our Latest Analysis on HSCS
HeartSciences Company Profile
HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.
HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.
Featured Stories
- Five stocks we like better than HeartSciences
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for HeartSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartSciences and related companies with MarketBeat.com's FREE daily email newsletter.
